November 30, 2016 - By Peter Kolinski
New York: Globus Medical (NYSE:GMED) coverage was started with a “Buy” rating by stock analysts at Aegis Capital. This was revealed to clients and investors in an analyst report on Wednesday morning.
Out of 9 analysts covering Globus Medical Inc (NYSE:GMED), 2 rate it a “Buy”, 2 “Sell”, while 5 “Hold”. This means 22% are positive. $32 is the highest target while $21 is the lowest. The $26.75 average target is 23.05% above today’s ($21.74) stock price. Globus Medical Inc has been the topic of 17 analyst reports since August 3, 2015 according to StockzIntelligence Inc. The firm earned “Overweight” rating on Monday, September 28 by Morgan Stanley. The stock of Globus Medical Inc (NYSE:GMED) has “Underperform” rating given on Friday, January 8 by Bank of America. Morgan Stanley initiated the stock with “Overweight” rating in Monday, September 14 report. The firm has “Perform” rating given on Wednesday, November 9 by Oppenheimer. The stock has “Market Perform” rating given by Leerink Swann on Wednesday, July 27. On Friday, May 27 the stock rating was initiated by Barclays Capital with “Equal-Weight”. The stock has “Sell” rating given by Goldman Sachs on Monday, May 16. The firm has “Mkt Perform” rating by JMP Securities given on Wednesday, November 9. Barclays Capital maintained Globus Medical Inc (NYSE:GMED) rating on Wednesday, July 27. Barclays Capital has “Equalweight” rating and $25 price target. The stock of Globus Medical Inc (NYSE:GMED) has “Market Perform” rating given on Wednesday, July 27 by Wells Fargo.
About 77,875 shares traded hands. Globus Medical Inc (NYSE:GMED) has declined 15.85% since April 27, 2016 and is downtrending. It has underperformed by 21.08% the S&P500.
Analysts await Globus Medical Inc (NYSE:GMED) to report earnings on February, 22. They expect $0.33 earnings per share, up 3.13% or $0.01 from last year’s $0.32 per share. GMED’s profit will be $31.72 million for 16.47 P/E if the $0.33 EPS becomes a reality. After $0.29 actual earnings per share reported by Globus Medical Inc for the previous quarter, Wall Street now forecasts 13.79% EPS growth.
Insitutional Activity: The institutional sentiment decreased to 0.88 in 2016 Q2. Its down 0.33, from 1.21 in 2016Q1. The ratio is negative, as 21 funds sold all Globus Medical Inc shares owned while 61 reduced positions. 25 funds bought stakes while 74 increased positions. They now own 65.87 million shares or 1.65% less from 66.98 million shares in 2016Q1.
Champlain Investment Prtnrs Ltd Liability Com accumulated 1.39M shares or 0.57% of the stock. Pnc Grp Inc Incorporated, a Pennsylvania-based fund reported 62,814 shares. Citigroup holds 0% of its portfolio in Globus Medical Inc (NYSE:GMED) for 4,135 shares. Paradigm Asset Mgmt owns 11,450 shares or 0% of their US portfolio. Van Berkom & Associate has 2.10M shares for 2.29% of their US portfolio. Kistler owns 17 shares or 0% of their US portfolio. Fifth Third Bank & Trust last reported 0.01% of its portfolio in the stock. Ftb Advsrs Inc has 0% invested in the company for 815 shares. Blackrock Invest Mngmt Lc owns 261,239 shares or 0.01% of their US portfolio. California Employees Retirement Systems has 0% invested in the company for 93,500 shares. Rice Hall James & Associates Ltd Company last reported 693,056 shares in the company. Quantbot Technology L P owns 11,605 shares or 0.03% of their US portfolio. Invesco Limited has invested 0.01% of its portfolio in Globus Medical Inc (NYSE:GMED). Principal Financial Gru has 14,733 shares for 0% of their US portfolio. Farmers Merchants has 0% invested in the company for 248 shares.
Globus Medical, Inc. is a medical device company. The company has a market cap of $2.09 billion. The Firm is focused on developing products for patients with musculoskeletal disorders. It has a 17.8 P/E ratio. It is focused on products to treat patients with spine disorders.
According to Zacks Investment Research, “Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania.”
Globus Medical, Inc., incorporated on March 3, 2003, is a medical device company. The Firm is focused on developing products for patients with musculoskeletal disorders. It is focused on products to treat patients with spine disorders. The Company’s products fall under categories, which include Innovative Fusion and Disruptive Technologies. The Innovative Fusion category products include fusion products to treat spinal disorders for the entire spine, and they can be used in various surgical approaches. The Disruptive Technologies category represents a shift in the treatment of spinal disorders by allowing for surgical procedures and the treatment of spinal disorders.
More news for Globus Medical Inc (NYSE:GMED) were recently published by: Valuewalk.com, which released: “Globus Medical Inc (GMED)’s Inside Job” on March 22, 2016. Globenewswire.com‘s article titled: “Globus Medical Reports Third Quarter 2016 Results” and published on November 08, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.